These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

540 related items for PubMed ID: 22468643

  • 1. OnabotulinumtoxinA (BOTOX®): a review of its use in the prophylaxis of headaches in adults with chronic migraine.
    Frampton JE.
    Drugs; 2012 Apr 16; 72(6):825-45. PubMed ID: 22468643
    [Abstract] [Full Text] [Related]

  • 2. OnabotulinumtoxinA (BOTOX®): a guide to its use in preventing headaches in adults with chronic migraine.
    Lyseng-Williamson KA, Frampton JE.
    CNS Drugs; 2012 Aug 01; 26(8):717-23. PubMed ID: 22784019
    [Abstract] [Full Text] [Related]

  • 3. OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program.
    Aurora SK, Dodick DW, Diener HC, DeGryse RE, Turkel CC, Lipton RB, Silberstein SD.
    Acta Neurol Scand; 2014 Jan 01; 129(1):61-70. PubMed ID: 24107267
    [Abstract] [Full Text] [Related]

  • 4. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
    Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF, PREEMPT Chronic Migraine Study Group.
    Headache; 2010 Jun 01; 50(6):921-36. PubMed ID: 20487038
    [Abstract] [Full Text] [Related]

  • 5. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
    Aurora SK, Winner P, Freeman MC, Spierings EL, Heiring JO, DeGryse RE, VanDenburgh AM, Nolan ME, Turkel CC.
    Headache; 2011 Oct 01; 51(9):1358-73. PubMed ID: 21883197
    [Abstract] [Full Text] [Related]

  • 6. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.
    Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF, PREEMPT 1 Chronic Migraine Study Group.
    Cephalalgia; 2010 Jul 01; 30(7):793-803. PubMed ID: 20647170
    [Abstract] [Full Text] [Related]

  • 7. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
    Silberstein SD, Blumenfeld AM, Cady RK, Turner IM, Lipton RB, Diener HC, Aurora SK, Sirimanne M, DeGryse RE, Turkel CC, Dodick DW.
    J Neurol Sci; 2013 Aug 15; 331(1-2):48-56. PubMed ID: 23790235
    [Abstract] [Full Text] [Related]

  • 8. Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials.
    Silberstein SD, Diener HC, Dodick DW, Sommer K, Lipton RB.
    Headache; 2024 Aug 15; 64(7):838-848. PubMed ID: 38982666
    [Abstract] [Full Text] [Related]

  • 9. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R, Schreiber C.
    Headache; 2008 Jun 15; 48(6):900-13. PubMed ID: 18047501
    [Abstract] [Full Text] [Related]

  • 10. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial.
    Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF, PREEMPT 2 Chronic Migraine Study Group.
    Cephalalgia; 2010 Jul 15; 30(7):804-14. PubMed ID: 20647171
    [Abstract] [Full Text] [Related]

  • 11. Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT.
    Silberstein SD, Dodick DW, Aurora SK, Diener HC, DeGryse RE, Lipton RB, Turkel CC.
    J Neurol Neurosurg Psychiatry; 2015 Sep 15; 86(9):996-1001. PubMed ID: 25500317
    [Abstract] [Full Text] [Related]

  • 12. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine.
    Lipton RB, Varon SF, Grosberg B, McAllister PJ, Freitag F, Aurora SK, Dodick DW, Silberstein SD, Diener HC, DeGryse RE, Nolan ME, Turkel CC.
    Neurology; 2011 Oct 11; 77(15):1465-72. PubMed ID: 21956721
    [Abstract] [Full Text] [Related]

  • 13. Assessing clinically meaningful treatment effects in controlled trials: chronic migraine as an example.
    Dodick DW, Turkel CC, DeGryse RE, Diener HC, Lipton RB, Aurora SK, Nolan ME, Silberstein SD.
    J Pain; 2015 Feb 11; 16(2):164-75. PubMed ID: 25464159
    [Abstract] [Full Text] [Related]

  • 14. OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine.
    Frampton JE, Silberstein S.
    Drugs; 2018 Apr 11; 78(5):589-600. PubMed ID: 29532439
    [Abstract] [Full Text] [Related]

  • 15. Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine.
    Diener HC, Dodick DW, Turkel CC, Demos G, Degryse RE, Earl NL, Brin MF.
    Eur J Neurol; 2014 Jun 11; 21(6):851-9. PubMed ID: 24628923
    [Abstract] [Full Text] [Related]

  • 16. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
    Winner PK, Sadowsky CH, Martinez WC, Zuniga JA, Poulette A.
    Headache; 2012 Sep 11; 52(8):1219-25. PubMed ID: 22607530
    [Abstract] [Full Text] [Related]

  • 17. Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study.
    Young WB, Ivan Lopez J, Rothrock JF, Orejudos A, Manack Adams A, Lipton RB, Blumenfeld AM.
    J Headache Pain; 2019 Feb 01; 20(1):12. PubMed ID: 30709333
    [Abstract] [Full Text] [Related]

  • 18. Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: Analysis of PREEMPT data.
    Dodick DW, Silberstein SD, Lipton RB, DeGryse RE, Adams AM, Diener HC.
    Cephalalgia; 2019 Jul 01; 39(8):945-956. PubMed ID: 31112399
    [Abstract] [Full Text] [Related]

  • 19. Real-world effectiveness of onabotulinumtoxinA treatment for the prevention of headaches in adults with chronic migraine in Australia: a retrospective study.
    Stark C, Stark R, Limberg N, Rodrigues J, Cordato D, Schwartz R, Jukic R.
    J Headache Pain; 2019 Jul 15; 20(1):81. PubMed ID: 31307383
    [Abstract] [Full Text] [Related]

  • 20. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program.
    Lipton RB, Rosen NL, Ailani J, DeGryse RE, Gillard PJ, Varon SF.
    Cephalalgia; 2016 Aug 15; 36(9):899-908. PubMed ID: 27288354
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.